Xalatan
- Generic Name: latanoprost ophthalmic
- Brand Name: Xalatan
- Drug Class: Antiglaucoma, Prostaglandin Agonists
Xalatan (Latanoprost Ophthalmic) side effects drug center
What Is Xalatan?
Xalatan (latanoprost) is a prostaglandin analogue ophthalmic solution used to treat pressure in the eye (glaucoma, ocular hypertension) by decreasing liquid in the eye. Xalantan is available as a generic drug.
What Are Side Effects of Xalatan?
Side effects of Xalatan include:
- blurred vision,
- burning/stinging/itching/redness of the eye after using the drops,
- feeling as if something is in the eye,
- changes in eyelash number/color/length/thickness,
- eyelid skin darkening,
- browning of the iris,
- watery eyes,
- dry eyes,
- eye discomfort,
- lid crusting/discomfort,
- increased sensitivity to light,
- cold or flu-like symptoms (stuffy nose, sneezing, sore throat),
- headache,
- dizziness, or
- muscle/joint pain.
Serious side effects include:
- oozing or eye discharge,
- chest pain,
- vision changes,
- light sensitivity, and
- redness, swelling, itching or pain in the eye.
Dosage for Xalatan
Xalatan (latanoprost) is available in an ophthalmic solution; strength is 0.005% (50 μg/mL). It is administered by an eyedropper. The amount is determined by the doctor.
What Drugs, Substances, or Supplements Interact with Xalatan?
Xalatan may interact with other drugs. Tell your doctor all medications and supplements you use.
Xalatan During Pregnancy and Breastfeeding
Benefits versus risks should be considered in pregnant women; it is not known if the drug is present in breast milk. Consult your doctor before breastfeeding. Use in pediatrics is not discussed; any use of this drug should be first discussed with a doctor, preferably an ophthalmologist.
Additional Information
Our Xalantan Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Stop using latanoprost and call your doctor at once if you have:
- eye swelling, redness, severe discomfort, crusting or drainage (may be signs of infection);
- red, swollen, or itchy eyelids;
- increased sensitivity to light;
- vision changes; or
- severe burning, stinging, or irritation after using this medicine.
Common side effects may include:
- watery eyes;
- itchy eyes;
- puffy eyelids;
- stinging, burning, or redness of the eyes;
- blurred vision;
- feeling like something is in your eye;
- your eyes may be more sensitive to light;
- darkened eye color; or
- eyelash thickening.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Read the entire detailed patient monograph for Xalatan (Latanoprost Ophthalmic)
SIDE EFFECTS
The following adverse reactions were reported in postmarketing experience and are discussed in greater detail in other sections of the label:
- Iris pigmentation changes [see WARNINGS AND PRECAUTIONS]
- Eyelid skin darkening [see WARNINGS AND PRECAUTIONS]
- Eyelash changes (increased length, thickness, pigmentation, and number of lashes) [see WARNINGS AND PRECAUTIONS]
- Intraocular inflammation (iritis/uveitis) [see WARNINGS AND PRECAUTIONS]
- Macular edema, including cystoid macular edema [see WARNINGS AND PRECAUTIONS]
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
XALATAN was studied in three multicenter, randomized, controlled clinical trials. Patients received 50 mcg/mL XALATAN once daily or 5 mg/mL active-comparator (timolol) twice daily. The patient population studied had a mean age of 65±10 years. Seven percent of patients withdrew before the 6-month endpoint.
Table 1: Ocular Adverse Reactions and Ocular
Signs/Symptoms Reported by 5-15% of Patients Receiving Latanoprost
| Symptom/Finding | Adverse Reactions (incidence (%)) | |
| Latanoprost (n=460) |
Timolol (n=369) |
|
| Foreign body sensation | 13 | 8 |
| Punctate keratitis | 10 | 9 |
| Stinging | 9 | 12 |
| Conjunctival hyperemia | 8 | 3 |
| Blurred vision | 8 | 8 |
| Itching | 8 | 8 |
| Burning | 7 | 8 |
| Increased pigmentation of the Iris | 7 | 0 |
Less than 1% of the patients treated with XALATAN required discontinuation of therapy because of intolerance to conjunctival hyperemia.
Table 2: Adverse Reactions
That Were Reported in 1-5% of Patients Receiving Latanoprost
| Adverse Reactions (incidence (%)) | ||
| Latanoprost (n=460) |
Timolol (n=369) |
|
| Ocular Events/Signs and Symptoms | ||
| Excessive tearing | 4 | 6 |
| Eyelid discomfort/pain | 4 | 2 |
| Dry eye | 3 | 3 |
| Eye pain | 3 | 3 |
| Eyelid margin crusting | 3 | 3 |
| Erythema of the eyelid | 3 | 2 |
| Photophobia | 2 | 1 |
| Eyelid edema | 1 | 3 |
| Systemic Events | ||
| Upper respiratory tract infection/nasopharyngitis/influenza | 3 | 3 |
| Myalgia/arthralgia/back pain | 1 | 0.5 |
| Rash/allergic skin reaction | 1 | 0.3 |
The ocular event/signs and symptoms of blepharitis have been identified as “commonly observed” through analysis of clinical trial data.
Postmarketing Experience
The following reactions have been identified during postmarketing use of XALATAN in clinical practice. Because they are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to XALATAN, or a combination of these factors, include:
Nervous System disorders: Dizziness; headache; toxic epidermal necrolysis
Eye Disorders: Eyelash and vellus hair changes of the eyelid (increased length, thickness, pigmentation, and number of eyelashes); keratitis; corneal edema and erosions; intraocular inflammation (iritis/uveitis); macular edema, including cystoid macular edema; trichiasis; periorbital and lid changes resulting in deepening of the eyelid sulcus; iris cyst; eyelid skin darkening; localised skin reaction on the eyelids; conjunctivitis; pseudopemphigoid of the ocular conjunctiva
Respiratory, Thoracic and Mediastinal Disorders: Asthma and exacerbation of asthma; dyspnea
Skin and Subcutaneous Tissue Disorders: Pruritus
Infections and Infestations: Herpes keratitis
Cardiac Disorders: Angina; palpitations; angina unstable
General Disorders and Administration Site Conditions: Chest pain
Read the entire FDA prescribing information for Xalatan (Latanoprost Ophthalmic)
© Xalatan Patient Information is supplied by Cerner Multum, Inc. and Xalatan Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.
